Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine + mRNA COVID vaccine-Duke University-COVID-19-Influenza
- Development stage
- Phase 4
- Lead developer
- Duke University
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
This clinical trial intervention refers to the co-administration of an mRNA-based COVID-19 vaccine (specifically Moderna's mRNA-1273) and a quadrivalent inactivated influenza vaccine (specifically Seqirus's cell culture-based vaccine). Conducted by Duke University in collaboration with the CDC Clinical Immunization Safety Assessment (CISA) Project, the study evaluated the safety and immunogenicity of simultaneous versus sequential administration in healthy children and adults aged 5 years and older. The mRNA component works by delivering genetic instructions for the SARS-CoV-2 spike protein to induce an immune response, while the influenza component provides inactivated viral antigens (hemagglutinin) from four circulating strains. Results from the trial indicated that concomitant administration is well-tolerated and does not result in significant immunological interference, supporting the feasibility of combined vaccination programs.
- Brand names
- Spikevax
- Other names
- Concomitant vs Sequential COVID-19 and Influenza VaccinationSimultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on influenza vaccine + mRNA COVID vaccine-Duke University-COVID-19-Influenza.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine + mRNA COVID vaccine-Duke University-COVID-19-Influenza.